Prescient Therapeutics Ltd

AU:PTX Australia Biotechnology
Market Cap
$37.76 Million
AU$60.99 Million AUD
Market Cap Rank
#23117 Global
#450 in Australia
Share Price
AU$0.06
Change (1 day)
-3.33%
52-Week Range
AU$0.04 - AU$0.11
All Time High
AU$0.30
Categories
Companies in Australia Biotechnology
About

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more

Prescient Therapeutics Ltd (PTX) - Net Assets

Latest net assets as of December 2025: AU$16.97 Million AUD

Based on the latest financial reports, Prescient Therapeutics Ltd (PTX) has net assets worth AU$16.97 Million AUD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$18.48 Million) and total liabilities (AU$1.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$16.97 Million
% of Total Assets 91.83%
Annual Growth Rate 6.79%
5-Year Change -44.26%
10-Year Change -12.49%
Growth Volatility 876.93

Prescient Therapeutics Ltd - Net Assets Trend (1989–2025)

This chart illustrates how Prescient Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Prescient Therapeutics Ltd (1989–2025)

The table below shows the annual net assets of Prescient Therapeutics Ltd from 1989 to 2025.

Year Net Assets Change
2025-06-30 AU$11.39 Million -36.97%
2024-06-30 AU$18.07 Million -30.71%
2023-06-30 AU$26.08 Million +55.56%
2022-06-30 AU$16.76 Million -17.94%
2021-06-30 AU$20.43 Million +82.58%
2020-06-30 AU$11.19 Million -21.88%
2019-06-30 AU$14.32 Million +51.72%
2018-06-30 AU$9.44 Million -19.90%
2017-06-30 AU$11.78 Million -9.43%
2016-06-30 AU$13.01 Million +192.38%
2015-06-30 AU$4.45 Million -11.47%
2014-06-30 AU$5.03 Million +381.30%
2012-06-30 AU$-1.79 Million -114.77%
2011-06-30 AU$-832.03K -398.40%
2010-06-30 AU$278.83K +146.13%
2009-06-30 AU$-604.48K -927.46%
2008-06-30 AU$73.05K -95.87%
2007-06-30 AU$1.77 Million -12.79%
2006-06-30 AU$2.03 Million -28.37%
2005-06-30 AU$2.83 Million -22.19%
2004-06-30 AU$3.64 Million +281.42%
2003-06-30 AU$953.60K -34.51%
2002-06-30 AU$1.46 Million -59.72%
2001-06-30 AU$3.61 Million +183.14%
2000-06-30 AU$1.28 Million -52.33%
1999-06-30 AU$2.68 Million +128.29%
1998-06-30 AU$1.17 Million +4720.30%
1997-06-30 AU$24.34K +158.57%
1996-06-30 AU$-41.55K +68.99%
1995-06-30 AU$-134.00K -139.88%
1994-06-30 AU$336.00K -38.46%
1993-06-30 AU$546.00K -53.37%
1992-06-30 AU$1.17 Million -29.42%
1991-06-30 AU$1.66 Million -7.42%
1990-06-30 AU$1.79 Million +67.32%
1989-06-30 AU$1.07 Million --

Equity Component Analysis

This analysis shows how different components contribute to Prescient Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 8255904000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$93.89 Million 824.51%
Other Comprehensive Income AU$1.57 Million 13.75%
Total Equity AU$11.39 Million 100.00%

Prescient Therapeutics Ltd Competitors by Market Cap

The table below lists competitors of Prescient Therapeutics Ltd ranked by their market capitalization.

Company Market Cap
Global Mofy Metaverse Limited Ordinary Shares
NASDAQ:GMM
 		$33.36 Million
SMG Swiss Marketplace Group AG
SW:SMG
 		$33.37 Million
Microsemi Corporation
F:MS7
 		$33.38 Million
United U Li Corporation Bhd
KLSE:7133
 		$33.39 Million
CastleNet Technology
TWO:8059
 		$33.36 Million
PT Hexindo Adiperkasa Tbk
F:HX1A
 		$33.35 Million
Blue Lagoon Resources Inc
OTCQB:BLAGF
 		$33.35 Million
Petrolimex Gas Corp JSC
VN:PGC
 		$33.35 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Prescient Therapeutics Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 18,067,288 to 11,387,172, a change of -6,680,116 (-37.0%).
  • Net loss of 7,322,531 reduced equity.
  • Other comprehensive income decreased equity by 628,100.
  • Other factors increased equity by 1,270,515.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-7.32 Million -64.31%
Other Comprehensive Income AU$-628.10K -5.52%
Other Changes AU$1.27 Million +11.16%
Total Change AU$- -36.97%

Book Value vs Market Value Analysis

This analysis compares Prescient Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.10x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.01x to 4.10x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1989-06-30 AU$11.20 AU$0.06 x
1990-06-30 AU$16.64 AU$0.06 x
1991-06-30 AU$15.27 AU$0.06 x
1992-06-30 AU$12.62 AU$0.06 x
1993-06-30 AU$5.88 AU$0.06 x
1994-06-30 AU$3.62 AU$0.06 x
1995-06-30 AU$-1.44 AU$0.06 x
1996-06-30 AU$-0.45 AU$0.06 x
1997-06-30 AU$0.26 AU$0.06 x
1998-06-30 AU$12.64 AU$0.06 x
1999-06-30 AU$19.09 AU$0.06 x
2000-06-30 AU$8.63 AU$0.06 x
2001-06-30 AU$22.18 AU$0.06 x
2002-06-30 AU$8.68 AU$0.06 x
2003-06-30 AU$5.83 AU$0.06 x
2004-06-30 AU$12.69 AU$0.06 x
2005-06-30 AU$8.09 AU$0.06 x
2006-06-30 AU$4.87 AU$0.06 x
2007-06-30 AU$3.19 AU$0.06 x
2008-06-30 AU$0.13 AU$0.06 x
2009-06-30 AU$-1.05 AU$0.06 x
2010-06-30 AU$0.35 AU$0.06 x
2011-06-30 AU$-0.89 AU$0.06 x
2012-06-30 AU$-1.56 AU$0.06 x
2014-06-30 AU$0.12 AU$0.06 x
2015-06-30 AU$0.09 AU$0.06 x
2016-06-30 AU$0.16 AU$0.06 x
2017-06-30 AU$0.06 AU$0.06 x
2018-06-30 AU$0.04 AU$0.06 x
2019-06-30 AU$0.06 AU$0.06 x
2020-06-30 AU$0.03 AU$0.06 x
2021-06-30 AU$0.03 AU$0.06 x
2022-06-30 AU$0.03 AU$0.06 x
2023-06-30 AU$0.04 AU$0.06 x
2024-06-30 AU$0.02 AU$0.06 x
2025-06-30 AU$0.01 AU$0.06 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Prescient Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -64.31%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -168.09%
  • • Asset Turnover: 0.30x
  • • Equity Multiplier: 1.28x
  • Recent ROE (-64.31%) is above the historical average (-297.24%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1989 -8.85% 0.00% 0.00x 6.32x AU$-195.90K
1990 12.95% 0.00% 0.00x 4.65x AU$45.60K
1991 -15.53% 0.00% 0.00x 5.00x AU$-361.70K
1992 -1.79% 0.00% 0.00x 5.85x AU$-138.10K
1993 -4.21% 0.00% 0.00x 10.16x AU$-77.60K
1994 -5.95% 0.00% 0.00x 17.56x AU$-53.60K
1995 0.00% 0.00% 0.00x 0.00x AU$5.40K
1997 -5370.64% 0.00% 0.00x 6.65x AU$-1.31 Million
1998 -87.89% 0.00% 0.00x 1.05x AU$-1.15 Million
1999 -53.21% 0.00% 0.00x 1.04x AU$-1.69 Million
2000 -189.50% -889.34% 0.20x 1.08x AU$-2.55 Million
2001 -63.44% -322.05% 0.17x 1.18x AU$-2.65 Million
2002 -181.80% -608.51% 0.23x 1.31x AU$-2.79 Million
2003 -328.75% -2035.11% 0.09x 1.71x AU$-3.23 Million
2004 -108.96% -2264.57% 0.04x 1.14x AU$-4.33 Million
2005 -141.31% -281.62% 0.34x 1.48x AU$-4.28 Million
2006 -228.16% -2212.92% 0.06x 1.83x AU$-4.83 Million
2007 -150.86% -172.85% 0.48x 1.84x AU$-2.84 Million
2008 -2427.04% -340.31% 0.30x 23.96x AU$-1.78 Million
2009 0.00% 0.00% 0.00x 0.00x AU$-1.29 Million
2010 -668.51% 0.00% 0.00x 5.62x AU$-1.89 Million
2011 0.00% 0.00% 0.00x 0.00x AU$-1.28 Million
2012 0.00% 0.00% 0.00x 0.00x AU$-1.71 Million
2014 -25.80% -15928.47% 0.00x 1.05x AU$-1.80 Million
2015 -47.94% -5337.44% 0.01x 1.10x AU$-2.58 Million
2016 -13.48% -16387.72% 0.00x 1.06x AU$-3.06 Million
2017 -21.79% -1544.72% 0.01x 1.04x AU$-3.75 Million
2018 -27.27% -273.90% 0.09x 1.06x AU$-3.52 Million
2019 -26.52% -5265.88% 0.00x 1.05x AU$-5.23 Million
2020 -29.68% -322.74% 0.09x 1.08x AU$-4.44 Million
2021 -20.31% -350.13% 0.06x 1.03x AU$-6.19 Million
2022 -30.53% -270.88% 0.11x 1.05x AU$-6.79 Million
2023 -26.86% -288.51% 0.09x 1.08x AU$-9.61 Million
2024 -45.60% -221.93% 0.18x 1.13x AU$-10.04 Million
2025 -64.31% -168.09% 0.30x 1.28x AU$-8.46 Million

Industry Comparison

This section compares Prescient Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $31,815,679
  • Average return on equity (ROE) among peers: -60.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Prescient Therapeutics Ltd (PTX) AU$16.97 Million -8.85% 0.09x $33.36 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million